Investigating Neural Biomarkers for Gait in Parkinson's Patients
Launched by SWISS FEDERAL INSTITUTE OF TECHNOLOGY · Apr 6, 2023
Trial Information
Current as of July 21, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking to understand how the brain works during movement in people with Parkinson's disease, particularly focusing on walking and balance issues. By studying these "neural biomarkers," researchers hope to develop personalized treatments that can help improve the quality of life for patients. Participants will take part in activities like walking and other movements while their brain activity is recorded to gather important information.
To join this study, participants must be between the ages of 65 and 74 and either have Parkinson's disease (specifically those with balance and gait problems) or be healthy individuals without any neurological or orthopedic conditions. Everyone must agree to the study procedures and provide their consent. Those who qualify will be asked to complete exercises while their brain activity is monitored, helping researchers learn more about how to better support people living with Parkinson's disease.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All participants
- • must have given informed consent as documented by signature
- • agree to comply with the study procedures
- • Healthy control group
- • no neurological, orthopedic, or rheumatologic disease history
- • no identified sensory impairment.
- • no epilepsy and self-diagnosed acute or chronic psychiatric disorders
- • Parkinson's Patients
- • non-tremor dominant idiopathic PD patients
- • presence of postural instability (UPDRS \>1 for postural instability \[17\]), gait disturbance, and absence of other causes of reduced balance
- • Implanted with Percept™ PC neurostimulator
- • Able to be in the stimulation OFF
- Exclusion Criteria:
- • Relevant cognitive impairment, with a score on Montréal Cognitive Assessment (MoCA) \< 20
- • History of physical or neurological condition that interferes with study procedures
- • Social and/or personal circumstances interfering with the ability to come to the session
About Swiss Federal Institute Of Technology
The Swiss Federal Institute of Technology (ETH Zurich) is a prestigious research university located in Switzerland, renowned for its cutting-edge scientific research and innovation. With a strong emphasis on interdisciplinary collaboration, ETH Zurich leverages its expertise in engineering, natural sciences, and technology to advance healthcare solutions through clinical trials. The institute is committed to improving patient outcomes and advancing medical knowledge by conducting rigorous, ethically-sound research that adheres to the highest standards of scientific integrity. Its distinguished faculty and state-of-the-art facilities position ETH Zurich as a leader in clinical research, fostering partnerships that bridge academia, industry, and healthcare institutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Vitznau, Luzern, Switzerland
Patients applied
Trial Officials
Olivier Lambercy, PhD
Principal Investigator
RELab, ETH Zürich
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported